Overview

M&K BioSciences, Inc. (M&K), based in Maryland, formerly known as L&J Biosciences, Inc. (L&J) is a biotechnology company with a global vision focusing on commercializing a proprietary and innovative suite of protein-related therapies and manufacturing platforms. The company's primary focus research and development (R&D) were degenerative neurologic disorders and other targets such as alopecia, Ubiquitin Proteasome System (UPS) related disorders, and pain controlling medicine without drug dependency.

L&J Biosciences, Inc. was divided into L&J Bio, Inc. and M&K BioSciences, Inc. Previous research members have moved to L&J Bio, and L&J Bio is planning to go public in the Korean stock market. M&K BioSciences is a consulting company focusing on R&D collaboration, cGMP manufacturing of protein-related products, and licensing out products in the Middle East. The company's CEO has invented a cell-mediated gene therapy product and finished the phase II clinical trial in the US. This product development experience by US FDA compliance can be an asset for future collaboration in the Middle East countries.